A Phase 3 study of HS-10241 + Almonertinib vs chemo in NSCLC with MET amplification after EGFR-TKI failure
Unknown Phase 3 NCT06110663
Study Description
A Study of a New Combination Therapy for Advanced Lung Cancer with Specific Gene Alterations
Study Details
- Registry ID:
- NCT06110663
- Conditions:
- Non-Small Cell Lung Cancer
- Phase:
- Phase 3
- Target Enrollment:
- 314 participants
- Start Date:
- Healthy Volunteers:
- No
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.